ESTRELLA IMMUNOPHARMA ($ESLA) posted quarterly earnings results for Q3 2026 on Monday, November 16th. The company reported earnings of -$0.17 per share, missing estimates of -$0.08 by $0.09. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market open this morning: -13.11%
You can see Quiver Quantitative's $ESLA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ESTRELLA IMMUNOPHARMA Hedge Fund Activity
We have seen 4 institutional investors add shares of ESTRELLA IMMUNOPHARMA stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 305,445 shares (-7.7%) from their portfolio in Q3 2026, for an estimated $142,551
- WELLS FARGO & COMPANY/MN removed 264,388 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $274,963
- VANGUARD FIDUCIARY TRUST CO added 29,475 shares (+45.4%) to their portfolio in Q3 2026, for an estimated $13,755
- RENAISSANCE TECHNOLOGIES LLC removed 24,400 shares (-62.4%) from their portfolio in Q3 2026, for an estimated $11,387
- US BANCORP \DE\ removed 20,000 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $9,334
- NORTHERN TRUST CORP added 15,237 shares (+77.6%) to their portfolio in Q2 2026, for an estimated $15,846
- ROYAL BANK OF CANADA removed 6,600 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $6,864
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.